The PDUFA date for Ligand Pharmaceutical's (LGND) CE Melphalan is Tuesday, September 30. The NDA was submitted by development and commercial partner Spectrum Pharmaceuticals (SPPI -0.9%). Captisol-enabled Melphalan is free of propylene glycol, which is associated with renal and cardiac side effects. Melphalan is a myeloablative therapy that is used prior to autologous stem cell transplantation
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.